Evidence map›Paper›PMID 30852181›Full record

ArticleJournal of neuroimmunology2019

Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.

Cecilie Ammitzbøll, Lars Börnsen, Eva Rosa Petersen, Annette Bang Oturai, Helle Bach Søndergaard, Philippe Grandjean, Finn Sellebjerg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimmunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cecilie AmmitzbøllDanish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address: cecilie.ammitzboell@regionh.dk.
Lars BörnsenDanish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Eva Rosa PetersenDanish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Annette Bang OturaiDanish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Helle Bach SøndergaardDanish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Philippe GrandjeanInstitute of Public Health, University of Southern Denmark, Odense, Denmark; Department of Environmental Health, Harvard School of Public Health, Boston, MA, United States.
Finn SellebjergDanish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
University of Copenhagen · DKUniversity of Southern Denmark · DK

Funding

Sources, Transport, Exposure & Effects of PFAS (STEEP) Center - RENEWALP42ES027706 · NIEHS · UNIVERSITY OF RHODE ISLAND · PI Harrison Dekker · 2017 to 2026
$18.9M
NIEHS NIH HHS P42 ES027706
6 · The paper itself

Abstract

Perfluorinated alkylated substances (PFASs) have immunomodulatory effects but the impact on multiple sclerosis (MS) and cellular immune functions is only sparsely described. In the present study, we found lower concentrations of the long chain PFAS perfluorooctane sulfonic acid (PFOS) in MS than in healthy controls (HC). In HC, we did not detect associations between PFOS concentrations and immune phenotypes. Analyzing the impact of known MS risk factors on cellular immune functions, we found that smoking and Epstein-Barr nuclear antigen 1 antibodies were associated with distinct circulating immune cell changes. In summary, current background PFAS exposure is not an important risk factor for MS.

Indexed as

AdultAlkanesulfonic AcidsCohort StudiesCross-Sectional StudiesFemaleFluorocarbonsHumansImmunity, CellularMaleMiddle AgedMultiple SclerosisRisk FactorsAlkanesulfonic AcidsFluorocarbonsperfluorooctane sulfonic acid

Identifiers

PMID30852181
PMCPMC6461219
OpenAlexW2919129553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.